Patents by Inventor Richard Antonius Jozef Janssen

Richard Antonius Jozef Janssen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
    Patent number: 10048250
    Abstract: The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic conditions. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of fibrotic conditions. The invention further provides in vitro methods for reduction or inhibition of macrophage differentiation into alternatively-activated macrophages (M2).
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: August 14, 2018
    Assignee: GALAPAGOS NV
    Inventors: Richard Antonius Jozef Janssen, Annemarie Nicolette Lekkerkerker, Thomas Van Es, Johannes Melchior Petrus Stallen
  • Methods of identifying compounds for the treatment of fibrosis by using S1PR5
    Patent number: 9952202
    Abstract: The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic diseases, in particular diseases related to fibroblast migration and differentiation. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of fibrotic disease. The invention further provides in vitro methods for inhibition of fibroblast migration and differentiation.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 24, 2018
    Assignee: GALAPAGOS NV
    Inventors: Richard Antonius Jozef Janssen, Annemarie Nicolete Lekkerkerker, Jamil Aarbiou, Krista Ouwehand
  • MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF FIBROTIC DISEASES
    Publication number: 20180045713
    Abstract: The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic conditions. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of fibrotic conditions. The invention further provides in vitro methods for reduction or inhibition of macrophage differentiation into alternatively-activated macrophages (M2).
    Type: Application
    Filed: August 4, 2017
    Publication date: February 15, 2018
    Inventors: Richard Antonius Jozef JANSSEN, Annemarie Nicolette LEKKERKERKER, Thomas VAN ES, Johannes Melchior Petrus STALLEN
  • MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF FIBROSIS
    Publication number: 20160069868
    Abstract: The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic diseases, in particular diseases related to fibroblast migration and differentiation. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of fibrotic disease. The invention further provides in vitro methods for inhibition of fibroblast migration and differentiation.
    Type: Application
    Filed: March 7, 2014
    Publication date: March 10, 2016
    Inventors: Richard Antonius Jozef JANSSEN, Annemarie Nicolete LEKKERKERKER, Jamil AARBIOU, Krista OUWEHAND
  • MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF FIBROTIC DISEASES
    Publication number: 20160054304
    Abstract: The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic conditions. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of fibrotic conditions. The invention further provides in vitro methods for reduction or inhibition of macrophage differentiation into alternatively-activated macrophages (M2).
    Type: Application
    Filed: March 7, 2014
    Publication date: February 25, 2016
    Inventors: Richard Antonius Jozef Janssen, Annemarie Nicolete Lekkerkerker, Thomas Van Es, Johannes Melchior Petrus Stallen
  • MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF DISEASES ASSOCIATED WITH EPITHELIAL MESENCHYMAL TRANSITION
    Publication number: 20160003808
    Abstract: The present invention relates to methods and assays for identifying agents useful in the treatment of diseases associated with epithelial mesenchymal transition (EMT), in particular fibrotic diseases and cancer. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of diseases associated with epithelial mesenchymal transition, in particular fibrotic disease and cancer. The invention further provides in vitro methods for inhibition of epithelial mesenchymal transition.
    Type: Application
    Filed: March 7, 2014
    Publication date: January 7, 2016
    Inventors: Richard Antonius Jozef Janssen, Annemarie Nicolete Lekkerkerker, Jamil Aarbiou
  • Methods for Identifying and Compounds Useful for Increasing the Functional Activity and Cell Surface Expression of CF-Associated Mutant Cystic Fibrosis Transmembrance Conductance Regulator
    Publication number: 20140256790
    Abstract: The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the modulation of cellular trafficking of proteins in particular that of CF-associated mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by an ER-associated protein misfolding and abnormal cellular trafficking of disease-associated proteins, including cystic fibrosis (CF).
    Type: Application
    Filed: May 20, 2014
    Publication date: September 11, 2014
    Inventors: David Frederik Fischer, Richard Antonius Jozef Janssen, Marjet Roseboom, Amelia Katie Scaffidi, Michela Angela Tessari
  • Methods for identifying and compounds useful for increasing the functional activity and cell surface expression of CF-associated mutant cystic fibrosis transmembrane conductance regulator
    Patent number: 8765376
    Abstract: The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the modulation of cellular trafficking of proteins in particular that of CF-associated mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by an ER-associated protein misfolding and abnormal cellular trafficking of disease-associated proteins, including cystic fibrosis (CF).
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: July 1, 2014
    Assignee: Galapagos NV
    Inventors: David Frederik Fischer, Richard Antonius Jozef Janssen, Marjet Roseboom, Amelia Katie Scaffidi, Michela Tessari
  • METHODS FOR IDENTIFYING AND COMPOUNDS USEFUL FOR THE DIAGNOSIS AND TREATMENT OF DISEASES INVOLVING INFLAMMATION
    Publication number: 20120035245
    Abstract: The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the stabilization of mast cells, in particular that inhibit mast cell degranulation. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by mast cell degranulation and/or inflammation, including allergic rhinitis.
    Type: Application
    Filed: February 18, 2010
    Publication date: February 9, 2012
    Inventors: Richard Antonius Jozef Janssen, Anton De Groot, Annemarie Nicolette Lekkerkerker, Eric Charles Meldrum, Nicola Thompson
  • METHODS FOR IDENTIFYING AND COMPOUNDS USEFUL FOR THE DIAGNOSIS AND TREATMENT OF DISEASES INVOLVING INFLAMMATION
    Publication number: 20120004160
    Abstract: The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the inhibition of the activation of macrophages. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by activation of macrophages including infections, allograft reactions, inflammation, allergic and autoimmune diseases, metabolic disease, cardiovascular disease, tissue injury, and cancer.
    Type: Application
    Filed: February 18, 2010
    Publication date: January 5, 2012
    Applicants: Glaxo Group Ltd., Bio-Focus DPI B.V.
    Inventors: Richard Antonius Jozef Janssen, Anton De Groot, Annemarie Nicolette Lekkerkerker, Eric Charles Meldrum, Nicola Thompson, Marion Catherine Dickson, Keith Paul Ray, Susan Heather Boyce
  • METHODS FOR IDENTIFYING AND COMPOUNDS USEFUL FOR THE DIAGNOSIS AND TREATMENT OF DISEASES INVOLVING INFLAMMATION
    Publication number: 20110306655
    Abstract: The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the inhibition of the maturation of dendritic cells. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by maturation of dendritic cells including infections, allograft reactions, inflammation, allergic and autoimmune diseases, and cancer.
    Type: Application
    Filed: February 18, 2010
    Publication date: December 15, 2011
    Inventors: Richard Antonius Jozef Janssen, Anton De Groot, Annemarie Nicolette Lekkerkerker, Eric Charles Meldrum, Nicola Thompson, Dilniya Fattah
  • METHODS FOR IDENTIFYING AND COMPOUNDS USEFUL FOR INCREASING THE FUNCTIONAL ACTIVITY AND CELL SURFACE EXPRESSION OF CF-ASSOCIATED MUTANT CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20110245322
    Abstract: The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the modulation of cellular trafficking of proteins in particular that of CF-associated mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by an ER-associated protein misfolding and abnormal cellular trafficking of disease-associated proteins, including cystic fibrosis (CF).
    Type: Application
    Filed: September 10, 2009
    Publication date: October 6, 2011
    Inventors: David Frederik Fischer, Richard Antonius Jozef Janssen, Marjet Roseboom, Amelia Katie Scaffidi, Michela Tessari
  • MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20110077283
    Abstract: The present invention relates to methods and assays for identifying agents capable of inhibiting the mutant huntingtin protein, inhibiting or reducing polyglutamine-induced protein aggregation, and/or altering huntingtin protein conformation, which inhibition is useful in the prevention, amelioration and/or treatment of neurodegenerative diseases, and protein aggregation diseases more generally. In particular, the present invention provides methods and assays for identifying agents for use in the prevention and/or treatment of Huntington's disease.
    Type: Application
    Filed: February 3, 2009
    Publication date: March 31, 2011
    Inventors: David Frederik Fischer, Richard Antonius Jozef Janssen, Remko De Pril, Desiré Maria Petronella Catharina Van Steenhoven, Seung Kwak, David S. Howland, Ethan Signer